113 related articles for article (PubMed ID: 9806658)
1. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate.
Vollmer RT; Dawson NA; Vogelzang NJ
Cancer; 1998 Nov; 83(9):1989-94. PubMed ID: 9806658
[TBL] [Abstract][Full Text] [Related]
2. A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies.
Vollmer RT; Kantoff PW; Dawson NA; Vogelzang NJ
Clin Cancer Res; 1999 Apr; 5(4):831-7. PubMed ID: 10213219
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma.
Diamandis EP; Helle SI; Yu H; Melegos DN; Lundgren S; Lonning PE
Cancer; 1999 Feb; 85(4):891-8. PubMed ID: 10091767
[TBL] [Abstract][Full Text] [Related]
4. Importance of serum hemoglobin in hormone refractory prostate cancer.
Vollmer RT; Kantoff PW; Dawson NA; Vogelzang NJ
Clin Cancer Res; 2002 Apr; 8(4):1049-53. PubMed ID: 11948112
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients.
Oudard S; Banu E; Scotte F; Banu A; Medioni J; Beuzeboc P; Joly F; Ferrero JM; Goldwasser F; Andrieu JM
Ann Oncol; 2007 Nov; 18(11):1828-33. PubMed ID: 17846024
[TBL] [Abstract][Full Text] [Related]
7. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.
Dawson NA; Conaway M; Halabi S; Winer EP; Small EJ; Lake D; Vogelzang NJ
Cancer; 2000 Feb; 88(4):825-34. PubMed ID: 10679652
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of megestrol acetate as monotherapy in disseminated prostatic carcinoma].
Gallo Rolania FJ
Arch Esp Urol; 1998 Mar; 51(2):151-3. PubMed ID: 9586312
[TBL] [Abstract][Full Text] [Related]
9. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men.
Vollmer RT; Egawa S; Kuwao S; Baba S
Cancer; 2002 Mar; 94(6):1692-8. PubMed ID: 11920530
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
J Clin Oncol; 1995 Dec; 13(12):2944-53. PubMed ID: 8523059
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
Rozhansky F; Chen MH; Cox MC; Dahut W; Figg WD; D'Amico AV
Cancer; 2006 Jan; 106(1):63-7. PubMed ID: 16333854
[TBL] [Abstract][Full Text] [Related]
12. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer.
Wehbe TW; Stein BS; Akerley WL
Mayo Clin Proc; 1997 Oct; 72(10):932-4. PubMed ID: 9379696
[TBL] [Abstract][Full Text] [Related]
14. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
Heng DY; Chi KN
Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
Semeniuk RC; Venner PM; North S
Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
[TBL] [Abstract][Full Text] [Related]
16. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone.
Morioka M; Kobayashi T; Furukawa Y; Jo Y; Shinkai M; Matsuki T; Yamamoto T; Tanaka H
Urol Int; 2002; 68(1):10-5. PubMed ID: 11803262
[TBL] [Abstract][Full Text] [Related]
18. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
[TBL] [Abstract][Full Text] [Related]
19. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
